Author

M. Kiso

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 4 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Research Focus:host-pathogen & immune response· 4 Organism:mouse· 4 Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Assay:imaging· 1 Organism:non-human primate· 1

Frequent Co-Authors

K. Iwatsuki-Horimoto· 5 shared M. Imai· 5 shared Y. Kawaoka· 5 shared M. Ito· 4 shared N. Ohmagari· 3 shared S. Yamayoshi· 3 shared T. Suzuki· 3 shared Y. Sakai-Tagawa· 3 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersMicrobiology

K. Iwatsuki-Horimoto

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Characterization of an EG.5.1 clinical isolate in vitro and in vivo

R. Uraki, M. Kiso, K. Iwatsuki-Horimoto, S. Yamayoshi, M. Ito, S. Chiba, Y. Sakai-Tagawa, M. Imai, Y. Kashima, M. Koga, N. Fuwa, N. Okumura, M. Hojo, N. Iwamoto, H. Kato, , Y. Kawaoka

This study characterizes the in vitro and in vivo properties of the EG.5.1 SARS-CoV-2 variant, showing increased transmissibility and altered antigenicity compared to XBB.1.5.

bioRxiv · Aug 31, 2023 · PreprintMicrobiology

Characterization of SARS-CoV-2 Omicron BA.2.75 clinical isolates

R. Uraki, S. Iida, P. J. Halfmann, S. Yamayoshi, Y. Hirata, K. Iwatsuki-Horimoto, M. Kiso, M. Ito, Y. Furusawa, H. Ueki, Y. Sakai-Tagawa, M. Kuroda, T. Maemura, T. Kim, S. Mine, , Y. Kawaoka

This study evaluates the replicative ability and pathogenicity of SARS-CoV-2 BA.2.75 isolates in Syrian hamsters, finding higher lung replication and focal pneumonia compared to BA.2 and BA.5.

bioRxiv · Aug 26, 2022 · PreprintMicrobiology

Highly-Neutralizing COVID-19-Convalescent-Plasmas Potently Block SARS-CoV-2 Replication and Pneumonia in Syrian Hamsters.

Y. Takamatsu, M. Imai, K. Maeda, N. Nakajima, N. Higashi-Kuwata, K. Iwatsuki-Horimoto, M. Ito, M. Kiso, T. Maemura, Y. Takeda, K. Omata, T. Suzuki, Y. Kawaoka, H. Mitsuya

This study shows that highly-neutralizing COVID-19 convalescent plasmas significantly reduce SARS-CoV-2 viral titers and lung lesions in Syrian hamsters compared to moderately neutralizing plasmas.

bioRxiv · Jun 29, 2021Microbiology

Optimization of an LNP-mRNA vaccine candidate targeting SARS-CoV-2 receptor-binding domain

K. Kobiyama, M. Imai, N. Jounai, M. Nakayama, K. Hioki, K. Iwatsuki-Horimoto, S. Yamayoshi, J. Tsuchida, T. Niwa, T. Suzuki, M. Ito, S. Yamada, T. Watanabe, M. Kiso, H. Negishi, , K. J. Ishii

This study optimizes an LNP-mRNA vaccine targeting SARS-CoV-2 RBD by removing reactogenic materials, improving immunogenicity and protection in macaques.

bioRxiv · Mar 4, 2021 · PreprintImmunology

The anticoagulant nafamostat potently inhibits SARS-CoV-2 infection in vitro: an existing drug with multiple possible therapeutic effects

M. Yamamoto, M. Kiso, Y. Sakai-Tagawa, K. Iwatsuki-Horimoto, M. Imai, M. Takeda, N. Kinoshita, N. Ohmagari, J. Gohda, K. Semba, Z. Matsuda, Y. Kawaguchi, Y. Kawaoka, J.-i. Inoue

This study shows nafamostat inhibits SARS-CoV-2 infection in vitro by blocking TMPRSS2-mediated fusion, with potency exceeding its blood concentration, suggesting it as a potential COVID-19 treatment.

bioRxiv · Apr 22, 2020 · PreprintMicrobiology